Robert E Bristow1, Bryan E Palis, Dennis S Chi, William A Cliby. 1. The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD, USA. rbristow@uci.edu
Abstract
OBJECTIVE: To examine the effect of hospital procedure volume and other prognostic variables on overall survival outcome and likelihood of receiving standard recommended care among patients with advanced-stage epithelial ovarian cancer. METHODS: The National Cancer Data Base (NCDB) was searched for patients undergoing primary treatment for FIGO Stage IIIC/IV epithelial ovarian cancer from 1996 to 2005. The average annual surgical procedure volume was derived for each reporting hospital. Quartile ranking discriminated four groups of hospitals based on annual surgical volume: low (<9), intermediate (9-20), high (21-35), and very high (>35). Cox proportional hazards modeling was used to determine the impact on overall survival of hospital surgical volume adjusted for treatment, FIGO/AJCC stage, ethnicity, age, payer status, household income, and tumor grade. Binomial multivariate logistic regression modeling was used to assess differences in patient demographic, tumor, and treatment variables between high/very high volume hospitals and low/intermediate volume hospitals. RESULTS: A total of 45,929 patients were identified. After adjusting for other factors, overall survival was significantly correlated with hospital case volume: very high (reference); high (HR 0.98, 95% CI=0.92-1.04); intermediate (HR 1.08, 95% CI=1.01-1.15); and low (HR 1.14, 95% CI=1.07-1.22). Compared to low and intermediate volume hospitals, patients treated at very high and high-volume hospitals were less likely to receive neo-adjuvant chemotherapy (OR=0.33, 95% CI=1.18-1.50) or surgery alone (OR=0.77, 95% CI=0.73-0.82) instead of initial surgery and adjuvant chemotherapy. CONCLUSIONS: Hospital ovarian cancer surgical volume >or=21 cases/year is associated with a higher likelihood of patients with Stage IIIC/IV epithelial ovarian cancer receiving standard treatment (surgery followed by adjuvant chemotherapy). Even after adjusting for treatment paradigm and other factors, hospital volume >or=21 cases/year was significantly predictive of improved overall survival outcome. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: To examine the effect of hospital procedure volume and other prognostic variables on overall survival outcome and likelihood of receiving standard recommended care among patients with advanced-stage epithelial ovarian cancer. METHODS: The National Cancer Data Base (NCDB) was searched for patients undergoing primary treatment for FIGO Stage IIIC/IV epithelial ovarian cancer from 1996 to 2005. The average annual surgical procedure volume was derived for each reporting hospital. Quartile ranking discriminated four groups of hospitals based on annual surgical volume: low (<9), intermediate (9-20), high (21-35), and very high (>35). Cox proportional hazards modeling was used to determine the impact on overall survival of hospital surgical volume adjusted for treatment, FIGO/AJCC stage, ethnicity, age, payer status, household income, and tumor grade. Binomial multivariate logistic regression modeling was used to assess differences in patient demographic, tumor, and treatment variables between high/very high volume hospitals and low/intermediate volume hospitals. RESULTS: A total of 45,929 patients were identified. After adjusting for other factors, overall survival was significantly correlated with hospital case volume: very high (reference); high (HR 0.98, 95% CI=0.92-1.04); intermediate (HR 1.08, 95% CI=1.01-1.15); and low (HR 1.14, 95% CI=1.07-1.22). Compared to low and intermediate volume hospitals, patients treated at very high and high-volume hospitals were less likely to receive neo-adjuvant chemotherapy (OR=0.33, 95% CI=1.18-1.50) or surgery alone (OR=0.77, 95% CI=0.73-0.82) instead of initial surgery and adjuvant chemotherapy. CONCLUSIONS: Hospital ovarian cancer surgical volume >or=21 cases/year is associated with a higher likelihood of patients with Stage IIIC/IV epithelial ovarian cancer receiving standard treatment (surgery followed by adjuvant chemotherapy). Even after adjusting for treatment paradigm and other factors, hospital volume >or=21 cases/year was significantly predictive of improved overall survival outcome. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Jason D Wright; Yongmei Huang; Alexander Melamed; Ana I Tergas; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Obstet Gynecol Date: 2019-06 Impact factor: 7.661
Authors: Robert E Bristow; Jenny Chang; Argyrios Ziogas; Daniel L Gillen; Lu Bai; Veronica M Vieira Journal: Am J Obstet Gynecol Date: 2015-01-31 Impact factor: 8.661
Authors: Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver Journal: J Am Coll Surg Date: 2015-02-14 Impact factor: 6.113
Authors: Jinhai Huo; David R Lairson; Xianglin L Du; Wenyaw Chan; Jing Jiang; Thomas A Buchholz; B Ashleigh Guadagnolo Journal: Am J Clin Oncol Date: 2016-10 Impact factor: 2.339
Authors: Renee A Cowan; Roisin E O'Cearbhaill; Ginger J Gardner; Douglas A Levine; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; William P Tew; Evis Sala; Yulia Lakhman; Hebert A Vargas Alvarez; Debra M Sarasohn; Svetlana Mironov; Nadeem R Abu-Rustum; Dennis S Chi Journal: Ann Surg Oncol Date: 2015-10-28 Impact factor: 5.344
Authors: Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby Journal: J Natl Cancer Inst Date: 2013-03-28 Impact factor: 13.506